This Month in AJP  by unknown
This Month in AJP
Analysis of Telomere Length in Specific Cells in Paraffin-Embedded Sections of Human Tissues
Telomeres are DNA sequences complexed with proteins located at the ends of each chromosome. In humans, a typical
telomere DNA tract contains 1000 to 2000 tandem repeats of the sequence TTAGGG. Shortening of telomeres occurs at
every cell division and may be caused by oxidative injury. Telomere activity increases telomere length and may
immortalize cells in culture. Of particular interest is the finding that telomerase activity is detected in a large number of
human cancers while it is not present in differentiated cells. Methods for the measurement of telomere length by
fluorescent in situ hybridization (FISH) of metaphase chromosome spreads have been developed. Meeker et al (Am J
Pathol 2002, 160:1259-1268) describe a method for quantitative assessment of telomere length which can be applied for
formalin-fixed, paraffin-embedded human tissues. The assay requires only 10 to 15 cells and is adequate for small tissue
samples and biopsies. Moreover, the telomere measuring technique can be combined with antibody detection by
immunofluorescence, which permits the identification of specific cells for telomere analysis. Meeker and al used this
novel technique to compare telomere lengths between tumor and normal epithelial cells in prostate sections.
Loss of DNA Mismatch Repair and Microsatellite Instability Is Similar in Adenomas and
Carcinomas in Hereditary Nonpolyposis Colorectal Cancer
Germline mutations in DNA mismatch repair (MMR) loci are present in adenomas and colorectal carcinomas from
individuals with hereditary nonpolyposis colorectal cancer (HNPCC). Loss of MMR causes microsatellite instability
causing a large increase in mutation rats in simple DNA repeat sequences or at microsatellite loci. Deletions in long polyA
repeats are sensitive indicators of microsatellite instability. Because the deletions take place in stepwise fashion, with
loss of a single or only a few bases at a time, the extent of deletions in polyA repeats can provide information about the
time interval since the loss of MMR. Kim et al (Am J Pathol 2002, 160:1503-1506) investigated at what time during tumor
progression loss of MMR takes place. If loss of MMR occurs very early in tumorigenesis and may precede mutations in
gatekeeper genes, the extent of deletions in polyA repeats should be similar between adenomas and carcinomas. Kim
et al examined the extent of deletions in non-encoding polyA sequences in 6 adenomas and 10 cancers in HNPCC
patients. Adenoma deletions were approximately the same as those in cancer. In addition, the extent of deletion in tumors
removed from patients under clinical surveillance compared to non-surveillance patients did not differ significantly. The
data demonstrate that microsatellite instability is quite extensive in both small adenomas and cancer. This finding is
consistent with the notion that loss of MMR in HNPCC patients occurs very early in the tumorigenic process, probably
before oncogene mutations.
Deficiency in DNA Mismatch Repair Enhances Endometrial Tumorigenesis Induced by Mutations
in the PTEN Suppressor Gene
Mutations in the PTEN suppressor gene are the most common alterations in uterine endometrioid carcinoma (UEC). In
addition, microsatellite instability resulting from defects of DNA mismatch repair occur in 20 to 45% of UEC. Both
alterations are also detectable in complex atypical hyperplasia, the immediate precursor lesion for UEC. One hundred
percent of mice lacking one wild-type copy of PTEN develop uterine complex atypical hyperplasia at 32 weeks and 20
to 25% of these mice develop invasive carcinoma at 40 weeks. Wang et al (Am J Pathol 2002, 160:1481-1486) generated
double mutant mice which are heterozygous for PTEN and deficient in DNA mismatch repair (Meh1 nulls). By 14 to 18
weeks, the frequency of loss of the wild-type PTEN allele in the double mutant mice was as high as that present in lesions
of 40-week-old PTEN heterozygous mice, and some of these mice already contained invasive lesions in the endometrium.
The data demonstrate that deficiency of DNA mismatch repair accelerates endometrial tumorigenesis induced by PTEN
mutations. The results also strongly suggest that the loss of the PTEN wild-type allele is an important step in the
development of these tumors.
Detection of Skp2 (S-Phase Kinase-Associated Protein 2) as a Marker for Cell Replication
in Lymphomas
Skp2 is a member of a family of proteins known as F-box proteins (Fbps) which share a 40 amino acid F-box motif. These
proteins form complexes that can ubiquitinate a large number of proteins, marking them for proteasome degradation.
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Skp2 is required for the G1-S transition of the cell cycle and interacts with the cyclin A-Cdk2 complex. Skp2 deficient mice
have slow growth while its overexpression in T cells causes oncogenesis in cooperation with ras genes. The cyclin-
dependent kinase (CDK) inhibitor p27, which is often inactivated in human tumors, is a Skp2 substrate. Chiarle et al (Am J
Pathol 2002, 160:1457-1466) demonstrate that Skp2 expression in lymphomas directly correlates with the grade of
malignancy and has an inverse correlation with p27 expression in a majority of lymphoma subtypes. Although Skp2 is
usually involved in p27 regulation, there are alternative pathways for regulation of this cell cycle inhibitor that may not
involve Skp2. Nevertheless, Skp2 detection by flow cytometry or immunohistochemistry matched measurements of
S-phase cells by DNA content, BrdU, and Ki-67 labeling. Detection of Skp2 offers a simple method to assess S-phase
cells in lymphomas and may have prognostic value.
Nitric Oxide Protects Against Ischemia-Reperfusion Injury in Skeletal Muscle
Nitric oxide (NO) generated by the activity of endothelial NO synthase (eNOS) is an important regulator of vascular
functions. Although NO is considered to be an important component of ischemia-reperfusion (I/R) tissue injury, it has not
been established whether NO has a cytoprotective or cytotoxic role in the development of I/R injury. Studies with NO
inhibitors have shown either protective or detrimental effects in this type of injury. Studies with transgenic mice, which
express eNOS mostly in endothelium, showed that these animals are protected against several types of injury. Ozaki et
al (Am J Pathol 2002, 160:1335-1344) investigated whether eNOS transgenic mice would be protected against I/R injury
in skeletal muscle. During reperfusion, superoxide levels were decreased by approximately 50% in the transgenic mice
compared to wild-type (WT) controls. In WT mice there were alterations in endothelial junctional proteins at the early
stages of reperfusion as well as increased vascular permeability. In contrast, eNOS transgenic mice had no abnormal-
ities in junctional proteins and no change in vascular permeability. Furthermore, in contrast to WT animals, leukocyte
extravasation, increased expression of adhesion molecules, and decreased tissue viability were significantly inhibited in
eNOS transgenics. This work demonstrates that eNOS overexpression and consequent NO production maintains
vascular integrity and prevents I/R injury in skeletal muscle.
Angiopoietin 1 and 2 Antagonism in Tumor Neovascularization
Tumor cells can produce angiogenic factors which stimulate the formation of new blood vessels required for tumor
growth. In addition to vascular endothelial growth factor (VEGF) and its receptors located in endothelial cells, another
system involving the endothelial tyrosine kinase receptor, Tie2, appears to be important in vascular development. Two
ligands have been identified that bind the Tie2 receptor: Angiopoietin1 (Ang1) which stimulates the receptor tyrosine
kinase, and Angiopoietin2 (Ang2) that acts as an antagonist for Ang1 by blocking receptor phosphorylation. Tie2
activation by Ang1 is believed to stabilize mature blood vessels. Ang2 is thought to block this effect and facilitate the
angiogenic response to VEGF. Although it is assumed that the Ang1/Ang2 system may play an important role in tumor
growth, experimental results have not been consistent. Hawighorst et al (Am J Pathol 2002, 160:1381-1392) analyzed the
effects of activation of the Tie2 receptor by Ang1 and Ang2 during mouse skin carcinogenesis and in xenografts of
squamous cell carcinomas. Expression of Ang2 but not of Ang1 was increased in tumor blood vessels even at the early
stages of tumorigenesis. Stable overexpression of Ang1 in tumor cells enhanced Tie2 phosphorylation and reduced
tumor growth. Blood vessels of these tumors had increased periendothelial cells containing -smooth muscle actin, an
indicator of vascular maturity. The data demonstrate that during tumor growth there is an angiogenic switch by which
Ang2 counteracts the vessel-maturation effects of Ang1.
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